White Paper

[Biosimilars are] the best chance we have to free up the financial space we need for everything else coming at us – CAR-T, I-O and even expanding access to some of the products we’ve already listed.
— Payer
There’s a different structure and relationship between the cancer agency and the ministry in each province. That really complicates us all trying to work together through pCPA.
— Clinician
There’s a risk that we get so excited about the savings and go so fast that we don’t lay the groundwork for successful launch. What’s tricky is that there are a lot of folks responsible for what a successful launch looks like.
— Payer
There are lots of questions about switching between biosimilars. The impact of multiple biosimilars in an area is something that deserves a lot more consideration.
— Patient Group
Biosimilars are going to be the opposite of how the reimbursement process usually works. In this case, clinicians are divided or uncertain and payers are ready to go. Usually we’re the ones clamouring for them to do a deal and this time they’re going to start clamouring for us to get on board.
— Clinician